Who
Christopher J. Senner
Director
Company insider
Files Form 4 as: Director, Quince Therapeutics; EVP and CFO, Exelixis.
In numbers
- Trades disclosed
- 137
- Buys
- 0
- Sells
- 17
- Bought
- $0
- Sold
- $28.6M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 15 Jul 2015
- Last trade
- 11 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Jun 2026filed 15 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,700 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,700 at $0.00 | filing |
| 18 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.7M34,901 at $50.00 | filing |
| 18 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.7M34,901 at $50.00 | filing |
| 15 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $2.1M40,892 at $51.10 | filing |
| 15 May 2026filed 19 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $2.1M40,892 at $51.10 | filing |
| 26 Feb 2026filed 2 Mar 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —52,018 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —52,018 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.3M30,617 at $43.67 | filing |
| 17 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.3M30,617 at $43.67 | filing |
| 15 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.6M35,870 at $43.92 | filing |
| 15 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.6M35,870 at $43.92 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.5M34,278 at $43.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $1.5M34,278 at $43.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —149,474 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.8M40,459 at $45.23 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —149,474 at $0.00 | filing |
| 15 Jan 2026filed 16 Jan 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code F | $1.8M40,459 at $45.23 | filing |
| 2 Jan 2026filed 21 Jan 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,810 at $0.00 | filing |
| 2 Jan 2026filed 21 Jan 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,810 at $0.00 | filing |
News
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockEXEL · tickerreport.com · 21 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Christopher J. Senner; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.